
Quarterly report 2023-Q2
added 08-11-2023
vTv Therapeutics Net Debt 2011-2026 | VTVT
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt vTv Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -11.6 M | -12.7 M | - | 5.34 M | 14 M | 7.83 M | -40.4 M | -88 M | 34.8 M | 82.1 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 82.1 M | -88 M | -973 K |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Autolus Therapeutics plc
AUTL
|
-32.7 M | $ 1.35 | -2.91 % | $ 359 M | ||
|
Coherus BioSciences
CHRS
|
-85.6 M | $ 1.61 | -3.59 % | $ 189 M | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Catalyst Pharmaceuticals
CPRX
|
-706 M | $ 24.88 | -0.4 % | $ 3.04 B | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
263 K | $ 10.02 | -1.16 % | $ 133 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Cardiff Oncology
CRDF
|
-16.6 M | $ 1.57 | -0.63 % | $ 105 M | ||
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 3.65 | 1.3 % | $ 8.78 B | ||
|
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | ||
|
DBV Technologies S.A.
DBVT
|
-188 M | $ 20.25 | -0.54 % | $ 2.83 B | ||
|
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | ||
|
Aytu BioScience
AYTU
|
-19.9 M | $ 2.55 | -4.14 % | $ 16 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Dyadic International
DYAI
|
-6.38 M | $ 0.87 | - | $ 31.5 M | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Entera Bio Ltd.
ENTX
|
-7.85 M | $ 1.17 | -2.1 % | $ 64 M | ||
|
Equillium
EQ
|
-29.6 M | $ 2.0 | -0.5 % | $ 115 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
Evogene Ltd.
EVGN
|
-3.44 M | $ 0.8 | 2.49 % | $ 27.9 M | ||
|
AIkido Pharma
AIKI
|
-31.2 M | - | 1.93 % | $ 17.4 M | ||
|
Fate Therapeutics
FATE
|
31.2 M | $ 1.15 | -3.78 % | $ 137 M | ||
|
Forte Biosciences
FBRX
|
-58.8 M | $ 26.15 | -1.1 % | $ 339 M | ||
|
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | ||
|
Fennec Pharmaceuticals
FENC
|
17.7 M | $ 6.2 | -3.43 % | $ 177 M | ||
|
Foghorn Therapeutics
FHTX
|
-39.6 M | $ 4.75 | -2.59 % | $ 299 M | ||
|
Amicus Therapeutics
FOLD
|
187 M | $ 14.46 | 0.03 % | $ 4.46 B | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | ||
|
BioNTech SE
BNTX
|
-973 M | $ 88.37 | -3.19 % | $ 27.2 B | ||
|
Akari Therapeutics, Plc
AKTX
|
-5.45 M | $ 3.52 | -0.56 % | $ 237 B | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
Fulcrum Therapeutics
FULC
|
-191 M | $ 7.45 | -4.85 % | $ 472 K | ||
|
Galectin Therapeutics
GALT
|
-25.6 M | $ 2.38 | -7.03 % | $ 152 M | ||
|
Allakos
ALLK
|
-25 M | - | - | $ 28.6 M | ||
|
Allena Pharmaceuticals
ALNA
|
-29.5 M | - | 3.16 % | $ 1.9 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
-604 M | $ 315.4 | -4.52 % | $ 41.3 B | ||
|
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B | ||
|
Gilead Sciences
GILD
|
14.7 B | $ 138.37 | -1.26 % | $ 172 B | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
-3.1 M | $ 0.54 | 4.26 % | $ 503 K | ||
|
Aileron Therapeutics
ALRN
|
-3.44 M | - | 10.36 % | $ 9.8 M | ||
|
Genmab A/S
GMAB
|
-6.94 B | $ 27.13 | -2.25 % | $ 17 B | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M |